In a nutshell This study evaluated the risk of heart-related (HR) side effects in patients with lung cancer treated with immune checkpoint inhibitors (ICI). Patients with lung cancer were shown to have a higher risk of developing HR side effects when treated with ICIs. Some background ICIs are a type of cancer therapy used to treat a wide variety of...
Read MoreTreatment(s) now being considered-Biological therapy Posts on Medivizor
Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?
In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some...
Read MoreCan erlotinib be used at a reduced dose to treat EGFR-mutated advanced non-small cell cancer?
In a nutshell This study was carried out to look at the use of a reduced dose of erlotinib (Tarceva) in the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC). The authors found that lower-dose erlotinib was as effective as standard dose gefitinib (Iressa) in these patients. Some background NSCLC is the...
Read MoreBenefits of autologous hematopoietic stem cell transplantation after checkpoint inhibitor therapy in patients with relapsed/refractory Hodgkin lymphoma
In a nutshell The study evaluated real-life benefits of autologous hematopoietic stem cell transplantation (ASCT) after immune checkpoint inhibitor (CPi) therapy in patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL). The authors found that ASCT can be an effective option after CPi therapy in such patients. Some background Some patients...
Read MoreComparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer
In a nutshell This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients. Some...
Read MoreImproving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.
In a nutshell This trial evaluated strategies to improve diarrhea as a side effect of neratinib (Nerlynx) treatment in patients with HER2-positive breast cancer (BC). The authors showed that slowly increasing the doses of neratinib or taking anti-diarrhea medication can improve this side effect. Some background Neratinib (Nerlynx) is a targeted...
Read MoreWhat side effects of the skin can biological therapy cause?
In a nutshell This article reviewed the skin side effects caused by anti-PD-1 biological therapy. Some background Anti-PD-1 is a type of biological therapy that has significantly improved treatment results for patients with certain types of cancer. It works by blocking PD-1, a molecule that cancer cells use to switch off the immune system. When the...
Read MoreWhat side effects of the skin can biological therapy cause?
In a nutshell This article reviewed the skin side effects caused by anti-PD-1 biological therapy. Some background Anti-PD-1 is a type of biological therapy that has significantly improved treatment results for patients with certain types of cancer. It works by blocking PD-1, a molecule that cancer cells use to switch off the immune...
Read MoreWhich scanning method is more accurate for patients with relapsed or refractory Hodgkin lymphoma who received biological therapy?
In a nutshell This study compared CT and PET scans to understand which was more accurate at predicting biological treatment results in patients with relapsed or refractory Hodgkin lymphoma (HL). The results showed that PET scans were more sensitive than CT scans in these patients. Some background Biological therapy has improved treatment results...
Read MoreLong-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer
In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...
Read MoreDo biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?
In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...
Read MoreHow effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?
In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....
Read More